ArticleWorld journal of surgical oncology2025
Comparative efficacy and safety of lenvatinib, sintilimab combined interventional therapy vs bevacizumab, sintilimab combined interventional therapy in intermediate and advanced hepatocellular carcinoma: a multicenter retrospective study.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundSystemic therapy combined with local intervention has demonstrated promising efficacy in patients with Unresectable hepatocellular carcinoma (uHCC). Bevacizumab plus sintilimab combined interventional treatment (BSIT) and lenvatinib plus sintilimab combined interventional treatment (LSIT) are widely used in clinical practice in China, but the optimal option remains unclear. This study aimed to compare the efficacy and safety of BSIT and LSIT in intermediate and advanced uHCC.
methodsPrimary endpoints were progression-free survival (PFS) and objective response rate (ORR); secondary endpoints included overall survival (OS), disease control rate (DCR), and treatment-related adverse events (TRAEs). Propensity score matching (PSM) was applied to reduce bias. Kaplan–Meier and multivariable Cox analyses were used to assess survival and prognostic factors.
resultsAfter PSM, 160 patients were assigned to BSIT (n = 80) and LSIT (n = 80). Survival outcomes, ORR, and DCR were similar between groups. Grade 3/4 AEs were comparable, except gastrointestinal bleeding, which was higher in BSIT. No grade 5 events occurred. Multivariate analysis revealed that extrahepatic metastasis and number of intrahepatic lesions independently predicted progression-free survival, while ECOG performance status was associated with overall survival.
conclusionsSintilimab plus lenvatinib or bevacizumab with interventional therapy showed comparable efficacy and tolerable safety in intermediate–advanced uHCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.